# US 2024/0173432 A1 · Compositions and Methods for Treatment of Myotonic Dystrophy Type 1 with CRISPR/SluCas9

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0173432 A1
- Document ID: US20240173432A1
- Status: Published application
- Kind: A1
- Application number: 18/456,288
- Filed: 2023-08-25
- Published: 2024-05-30
- Earliest claimed: 2021-02-26
- Assignees: Vertex Pharmaceuticals Incorporated
- Applicants: Vertex Pharmaceuticals Incorporated
- Inventors: Guoxiang Ruan; Jianming Liu; Tudor Fulga; Mehmet Fatih Bolukbasi; Eric Gunnar Anderson; Lingjun Rao; Norzehan Abdul-Manan; Matthias Heidenreich; Gregoriy Aleksandrovich Dokshin; Jesper Gromada
- Web page: https://patentgrep.com/patent/US20240173432A1

## CPC

- A61K 48/005: {characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered}
- C12N 15/1137: {against enzymes (viral enzymes C12N15/1131; receptors C12N15/1138)}
- A61K 31/506: not condensed and containing further heterocyclic rings
- A61K 31/5377: not condensed and containing further heterocyclic rings, e.g. timolol
- A61P 19/00: Drugs for skeletal disorders
- C12N 9/22: Ribonucleases {[RNase]; Deoxyribonucleases [DNase]}
- C12N 9/226: {Class 2 CAS enzyme complex, e.g. single CAS protein}
- C12N 15/11: DNA or RNA fragments; Modified forms thereof (DNA or RNA not used in recombinant technology, C07H21/00); {Non-coding nucleic acids having a biological activity}
- C12N 2310/20: involving clustered regularly interspaced short palindromic repeats [CRISPR]
- C12N 2750/14143: viral genome or elements thereof as genetic vector
- C12R 2001/44: Staphylococcus
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12R: INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS

## Abstract

Compositions and methods for treating Myotonic Dystrophy Type 1 (DM1) are encompassed.

## Claims

### Claim 1

A composition comprising a single nucleic acid molecule encoding one or more guide RNAs and a Cas9, wherein the single nucleic acid molecule comprises:
a. a first nucleic acid encoding one or more spacer sequence selected from any one of SEQ ID NOs: 1-65, 67-167, and 201-531 and a second nucleic acid encoding a Staphylococcus lugdunensis Cas9 (SluCas9);
b. a first nucleic acid encoding one or more spacer sequence comprising at least 20, or 21 contiguous nucleotides of a spacer sequence selected from any one of SEQ ID NOs: 1-65, 67-167, and 201-531 and a second nucleic acid encoding a Staphylococcus lugdunensis Cas9 (SluCas9);
c. a first nucleic acid encoding one or more spacer sequence that is at least 90% identical to any one of SEQ ID NOs: 1-65, 67-167, and 201-531 and a second nucleic acid encoding a Staphylococcus lugdunensis Cas9 (SluCas9);
d. a first nucleic acid encoding 2 spacer sequences selected from any one of SEQ ID NOs: 63 and 100, and 64 and 100, and a second nucleic acid encoding a Staphylococcus lugdunensis Cas9 (SluCas9); or
e. a first nucleic acid encoding one or more spacer sequence selected from any one of SEQ ID NOs: 8, 63, 64, and 81 and a second nucleic acid encoding a Staphylococcus lugdunensis Cas9 (SluCas9).

### Claim 2 (depends on 1)

The composition of claim 1, further comprising a DNA-PK inhibitor.

### Claim 3 (depends on 2)

The composition of claim 2, wherein the DNA-PK inhibitor is Compound 6, Compound 1, or Compound 2.

### Claim 4

(canceled)

### Claim 5

(canceled)

### Claim 6 (depends on 1)

The composition of claim 1, wherein the guide RNA is an sgRNA.

### Claim 7 (depends on 1)

The composition of claim 1, wherein the guide RNA is a modified guide RNA.

### Claim at position 8

-11. (canceled)

### Claim 12 (depends on 1)

The composition of claim 1, wherein the single nucleic acid molecule is associated with a lipid nanoparticle (LNP), or wherein the single nucleic acid molecule is associated with a viral vector.

### Claim 13

(canceled)

### Claim 14 (depends on 12)

The composition of claim 12, wherein the single nucleic acid molecule is associated with a viral vector, and wherein the viral vector is an adeno-associated virus vector, a lentiviral vector, an integrase-deficient lentiviral vector, an adenoviral vector, a vaccinia viral vector, an alphaviral vector, or a herpes simplex viral vector.

### Claim at position 12

-22. (canceled)

### Claim 23 (depends on 1)

The composition of claim 1, comprising a nucleic acid encoding SluCas9, wherein the SluCas9 comprises the amino acid sequence of any one of SEQ ID NOs: 712 or 718-720.

### Claim at position 14

-31. (canceled)

### Claim 32

A method of treating Myotonic Dystrophy Type 1 (DM1), the method comprising delivering to a cell a single nucleic acid molecule comprising a nucleic acid encoding a Staphylococcus lugdunensis Cas9 (SluCas9); and:
i) a nucleic acid encoding a guide RNA, wherein the guide RNA comprises:
a. one or more spacer sequence selected from any one of SEQ ID NOs: 1-65, 67-167, and 201-531;
b. one or more spacer sequence comprising at least 20, or 21 contiguous nucleotides of a spacer sequence selected from any one of SEQ ID NOs: 1-65, 67-167, and 201-531; or
c. one or more spacer sequence that is at least 90% identical to any one of SEQ ID NOs: 1-65, 67-167, and 201-531; or
ii) a nucleic acid encoding a pair of guide RNAs comprising:
a. a first spacer sequence selected from any one of SEQ ID NOs: 1-65 and a second spacer sequence selected from any one of SEQ ID NOs: 67-167;
b. a first and second spacer sequence comprising at least 20, or 21 contiguous nucleotides of any of the first and second spacer sequences of i) a.;
c. a first and second spacer sequence that is at least 90% identical to any of the first and second spacer sequences of i) a. or i) b.;
d. a first and second spacer, or one or more vectors encoding the pair of guide RNAs, wherein the first and second spacer sequences comprise any one of the following pairs of SEQ ID NOs; 6 and 72; 6 and 81; 6 and 84; 6 and 98; 6 and 100; 6 and 114; 6 and 122; 6 and 134; 6 and 139; 6 and 149; 6 and 166; 8 and 72; 8 and 72; 8 and 81; 8 and 84; 8 and 98; 8 and 100; 8 and 114; 8 and 122; 8 and 134; 8 and 139; 8 and 149; 8 and 166; 10 and 72; 10 and 81; 10 and 84; 10 and 98; 10 and 100; 10 and 114; 10 and 122; 10 and 134; 10 and 139; 10 and 149; 10 and 166; 21 and 72; 21 and 81; 21 and 84; 21 and 98; 21 and 100; 21 and 114; 21 and 122; 21 and 134; 21 and 139; 21 and 149; 21 and 166; 58 and 72; 58 and 81; 58 and 84; 58 and 98; 58 and 100; 58 and 114; 58 and 122; 58 and 134; 58 and 139; 58 and 149; 58 and 166; 62 and 72; 62 and 81; 62 and 84; 62 and 98; 62 and 100; 62 and 114; 62 and 122; 62 and 134; 62 and 139; 62 and 149; 62 and 166; 63 and 72; 63 and 81; 63 and 84; 63 and 98; 63 and 100; 63 and 114; 63 and 122; 63 and 134; 63 and 139; 63 and 149; 63 and 166; 64 and 72; 64 and 81; 64 and 84; 64 and 98; 64 and 100; 64 and 114; 64 and 122; 64 and 134; 64 and 139; 64 and 149; and 64 and 166; or
e. a first and second spacer, or one or more vectors encoding the pair of guide RNAs, wherein the first and second spacer sequences comprise SEQ ID NOs: 63 and 100 or SEQ ID NOs: 64 and 100.

### Claim 33

(canceled)

### Claim 34

(canceled)

### Claim 35

A method of excising a CTG repeat in the 3′ UTR of the DMPK gene, the method comprising delivering to a cell a single nucleic acid molecule comprising a nucleic acid encoding a Staphylococcus lugdunensis Cas9 (SluCas9); and:
i) a nucleic acid encoding a guide RNA, wherein the guide RNA comprises:
a. one or more spacer sequence selected from any one of SEQ ID NOs: 1-65, 67-167, and 201-531;
b. one or more spacer sequence selected from any one of SEQ ID NOs: 8, 63, 64, and 81;
c. one or more spacer sequence comprising at least 20, or 21 contiguous nucleotides of a spacer sequence selected from any one of SEQ ID NOs: 1-65, 67-167, and 201-531; or
d. one or more spacer sequence that is at least 90% identical to any one of SEQ ID NOs: 1-65, 67-167, and 201-531; or
ii) a nucleic acid encoding a pair of guide RNAs comprising:
a. a first spacer sequence selected from any one of SEQ ID NOs: 1-65 and a second spacer sequence selected from any one of SEQ ID NOs: 67-167;
b. a first and second spacer sequence comprising at least 20, or 21 contiguous nucleotides of any of the first and second spacer sequences of i) and;
c. a first and second spacer sequence that is at least 90% identical to any of the first and second spacer sequences of i) a. or i) b.; or
d. a first and second spacer sequence selected from any one of SEQ ID NOs: 63 and 100, and SEQ ID NOs: 64 and 100.

### Claim 36

(canceled)

### Claim 37

(canceled)

### Claim 38 (depends on 32)

The method of claim 32, comprising administering a DNA-PK inhibitor.

### Claim 39 (depends on 38)

The method of claim 38, wherein the DNA-PK inhibitor is Compound 6, Compound 1, or Compound 2.

### Claim 40

(canceled)

### Claim 41

(canceled)

### Claim 42 (depends on 32)

The method of claim 32, wherein the SluCas9 comprises the amino acid sequence of any one of SEQ ID NOs: 712 or 718-720.

### Claim 43

(canceled)

### Claim 44

(canceled)

### Claim 45 (depends on 1)

The composition of claim 1, wherein the nucleic acid encoding the gRNA or the nucleic acid encoding the pair of gRNAs comprises a sequence selected from any one of SEQ ID NOs: 600-601, or 900-917.

### Claim 46

(canceled)

### Claim 47 (depends on 1)

The composition of claim 1, wherein the nucleic acid molecule encodes at least a first guide RNA and a second guide RNA, and wherein the nucleic acid molecule further encodes a spacer sequence for the first guide RNA, a scaffold sequence for the first guide RNA, a spacer sequence for the second RNA, and a scaffold sequence for the second guide RNA.

### Claim at position 31

-52. (canceled)

### Claim 53 (depends on 48)

The composition of claim 48, wherein the scaffold sequence for the first guide RNA comprises a sequence selected from the group consisting of SEQ ID NOs: 901-916, and wherein the scaffold sequence for the second guide RNA comprises a different sequence selected from the group consisting of SEQ ID NOs: 901-916.

### Claim at position 33

-61. (canceled)

### Claim 62

A composition comprising a first nucleic acid molecule and a second nucleic acid molecule, wherein the first nucleic acid molecule encodes a Staphylococcus lugdunensis Cas9 (SluCas9) and the second nucleic acid molecule encodes one or more guide RNAs comprising:
a. one or more spacer sequence selected from any one of SEQ ID NOs: 1-65, 67-167, and 201-531;
b. one or more spacer sequence comprising at least 20, or 21 contiguous nucleotides of a spacer sequence selected from any one of SEQ ID NOs: 1-65, 67-167, and 201-531; or
c. one or more spacer sequence that is at least 90% identical to any one of SEQ ID NOs: 1-65, 67-167, and 201-531.

### Claim 63 (depends on 62)

The composition of claim 62, wherein the first nucleic acid molecule does not encode a guide RNA.

### Claim 64 (depends on 62)

The composition of claim 62, wherein the first nucleic acid molecule encodes:
a. one or more spacer sequence selected from any one of SEQ ID NOs: 1-65, 67-167, and 201-531;
b. one or more spacer sequence comprising at least 20, or 21 contiguous nucleotides of a spacer sequence selected from any one of SEQ ID NOs: 1-65, 67-167, and 201-531; or
c. one or more spacer sequence that is at least 90% identical to any one of SEQ ID NOs: 1-65, 67-167, and 201-531.

### Claim at position 37

-87. (canceled)
